Sensus Healthcare, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Sensus Healthcare reported Q2 2026 revenues of $2.3M (down $5.0M or 68.5% from $7.3M in Q2 2025), driven by only 11 units sold versus 19 in prior year and the deferral of 8 units' revenue recognition to Q3 due to financing approval delays. Net loss widened to $8.7M ($0.53/share) from $1.0M ($0.06/share) YoY, with a $5.7M tax valuation allowance recorded. Cash declined from $18.3M (Q1 2026) to $15.2M (Q2 2026). Positives include CMS's proposed 26% increase in hospital-based SRT delivery code reimbursement and expanded international activity in Asia-Pacific markets.
Why this rating
68.5% revenue drop and $8.7M net loss represent severe near-term deterioration for a $70.9M market-cap company; however, deferred sales and CMS reimbursement tailwinds provide partial mitigation and visibility into recovery.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.